Vyome vs Kazia Therapeutics
HIND and KZIA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HIND and KZIA compare
Vyome grew revenue faster over the last twelve months (−55.6% versus −98.2% for Kazia Therapeutics).
Vyome keeps more of each dollar of sales as profit, with a net margin of −2456% compared with −49291% at Kazia Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HIND | KZIA |
|---|---|---|
| Size and price | ||
| Market cap | $11.1M | – |
| Share price | $1.58 | $6.62 |
| Change, 1 year | −70.3% | −12.9% |
| Change, 5 years | −100.0% | −98.8% |
| Beta (5Y) | 1.56 | 1.38 |
| Employees | 18 | 14 |
| StockData Score | ||
| Total score | 1 | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 72.4× | – |
| Growth | ||
| Revenue growth (TTM) | −55.6% (better) | −98.2% |
| Revenue growth, 5Y average | −51.0% | – |
| Profitability | ||
| Gross margin | 50.4% | – |
| Operating margin | −2854% | – |
| Net margin | −2456% (better) | −49291% |
| Return on equity | −149% | – |
| Financial health | ||
| Interest coverage | −229.3× | – |
| Current ratio | 3.68 (better) | 2.87 |
| Altman Z-score | −12.31 | – |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −53.1% | – |
| Shareholder yield | −53.1% | – |
| Ownership | ||
| Held by institutions | 2.0% | 0.45% |
| Held by insiders | 6.8% | 0.29% |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 0.28% | – |
Go deeper
- HIND stock overview
- HIND income statement
- HIND valuation and score
- KZIA stock overview
- KZIA income statement
- KZIA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.